semaglutide gallatin tn TennCare's obesity medication coverage is a win for Tennesseans • Tennessee Lookout Semaglutide in Nashville | IntraVenous

J Clin Immunol 2004

No third-party batch reports have been uploaded for this product yet

Wegovy has been approved by the US Food and Drug Administration as a weight loss drug for adults who are obese, defined as a person whose BMI is greater than 30, as well as for people with a BMI of at least 27 who also have a weight-related condition, such as high blood pressure

Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously

Which one can I tolerate